Since atorvastatin is a pharmacological activator of KLF2 via the mevalonate13 and MEF2 (myocyte enhancer factor 2)-dependent pathways,14 we next asked whether overexpression of KLF2 via an adenoviral vector can also reverse patient-serum-induced endothelial dysfunction. Here, KLF2 is linked to endothelial dysfunction.